You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康諾亞-B(02162.HK)2024年度營收4.28億元 同比增長21%
格隆匯 03-24 21:20

格隆匯3月24日丨康諾亞-B(02162.HK)公佈年度業績,截至2024年12月31日止年度,公司收入為人民幣4.28億元,同比增長21%;毛利為人民幣4.16億元,同比增長31%;年內虧損為人民幣5.15億元,去年同期虧損3.57億元,於2024年12月31日,公司現金及現金等價物、定期存款及銀行理財產品總額為人民幣21.56億元。

截至2024年12月31日,公司共有1,258名全職僱員。其中,商業化團隊逾240人,藥物發現及臨牀運營團隊共計近400人。公司將持續招聘人才,以匹配不斷增長的產品商業化銷售、研發、臨牀、生產及公司運營的需求。截至公吿日期,公司的生產基地產能總計20,500升,所有設計均符合國家藥監局及FDA的cGMP規定。

公司將繼續在中國及全球(包括美國)迅速推進正在進行及計劃中的管線產品的臨牀方案,並籌備後期管線產品的商業化。同時,為了加快候選藥物的商業化進程,並將其商業價值最大化,公司將在中國及全球範圍內積極探索增值的戰略夥伴關係,如共同開發、合作及授權。

公司預期對候選藥物的生產需求將增加,計劃進一步擴大符合cGMP的生產能力,以提高生產的成本效益。公司欣然看到,目前已取得的迅速進展及未來詳細發展計劃與公司的願景一致。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account